Private Equity, VC & Investor
Creandum vs M13
Structured technology and market comparison · 2026
Direct Feature Comparison
Creandum · vs · M13Early-stage technology venture capital firm supporting international founder growth.
Early-stage venture capital firm backing market-creating founders.
Analyze all overlapping signals and tech stacks for Creandum and M13
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between Creandum and M13?
When comparing Creandum and M13, both platforms operate within the Private Equity, VC & Investor ecosystem. Creandum is positioned as Early-stage technology venture capital firm supporting international founder growth, whereas M13 focuses on Early-stage venture capital firm backing market-creating founders. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to Creandum and M13?
When evaluating Creandum and M13, enterprise buyers also consider other platforms in Private Equity, VC & Investor. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of Creandum and M13 compare?
Creandum is headquartered in United Kingdom (founded in 2003) with 50–200 employees. M13 is based in United States (founded in 2016) with 201–500 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: Creandum vs M13
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Creandum
Recent Signals
- ·EU-Startups (European Venture)Financials
Creandum closes €668M fund for early-stage startups
Stockholm-based venture capital firm Creandum has closed its largest fund to date, Creandum VIII, at €668 million ($750 million), surpassing its previous €500 million ($560 million) Fund VII. The fund will support approximately 30 early-stage investments from pre-Seed to Series A over the next two years, with half the capital allocated to new investments and the rest for follow-on rounds. Creandum is focusing on AI-driven opportunities, having recently invested in startups like Lovable, Olix, Modal, and Black Forest Labs. The firm has opened a new office in San Francisco, tripled its team there in the past year, and plans to expand its US presence while maintaining a generalist strategy. The fund secured commitments from about 30 institutional investors across Europe and the US.
- Creandum closed its largest fund, Creandum VIII, at €668 million ($750 million), up from €500 million Fund VII.
- The fund will support approximately 30 investments from pre-Seed to Series A, with half for new investments and half for follow-ons.
- The fund focuses on AI, with portfolio companies including Lovable, Olix, Modal, and Black Forest Labs.
- ·EU-Startups (European Venture)AI in Enterprise
London's Ares Intelligence Raises €2.9M for AI Adoption Platform
London-based Ares Intelligence, a startup developing an evidence-based platform for AI transformation, has raised €2.9 million (£2.48 million) in a funding round led by Creandum and Lakestar, with participation from angel investors connected to Google DeepMind. The platform uses an AI interviewer to conduct confidential voice conversations with employees in over 70 languages, generating a prioritised roadmap for AI adoption within weeks. Founded in 2026 by Matt Falconer and Alfie Ranstead, the company addresses the challenge of where to start with AI automation. Ares counts enterprise customers across Europe and the US, including Tremonia, a Mercedes-Benz spin-out, which identified over 400 hours of manual work savings per month. The new capital will support expansion and bring its workforce intelligence approach to more businesses.
- Ares Intelligence raised €2.9 million (£2.48 million) in funding.
- The round was backed by Creandum and Lakestar, with participation from angels connected to Google DeepMind.
- The platform uses an AI interviewer to collect employee insights in over 70 languages.
- ·Tech.eu (European Tech & Deals)AI in Drug Development
Atlas Bio Raises $12.5M for AI Clinical Trial Simulations
Swiss biotech startup Atlas Bio emerged from stealth with a total of $12.5 million in funding to develop an AI foundation model for in-silico clinical trials. The Seed round of $10 million was led by Creandum, with participation from First Momentum Ventures and LEA Partners, who also led a previously undisclosed pre-Seed round of $2.5 million. The company's model, trained on 2 million human RNA readouts, simulates patient-level drug efficacy and safety, aiming to replace Phase II trials and animal testing. Atlas Bio is already working with a top-10 global pharma company and a Basel-based biotech client that has eliminated animal testing in a specific workflow. The founders, Simon Romanski and Sebastian Bayer, emphasize the potential to reduce drug development costs and timelines significantly.
- Atlas Bio raised a $10M Seed round led by Creandum, plus a $2.5M pre-Seed round led by First Momentum Ventures and LEA Partners, totaling $12.5M.
- The company's AI model is trained on roughly 2 million RNA readouts from human tissue.
- Atlas Bio is working with a top 10 global pharma company and a Basel-based biotech client that has eliminated animal testing in a specific workflow.
M13
Recent Signals
- ·M13
What Is Agentic Identity? Meet Baselayer, the Identity Infrastructure for AI Agents
M13 announces fundraising for Baselayer, an identity infrastructure for AI agents, with a dedicated article published on September 22, 2026.
- ·NewcomerAgentic Commerce
Investors Are Betting on AI Agents That Shop for You
Venture capitalists are increasingly funding startups building AI agents that can shop on behalf of consumers and handle payments. The article maps the emerging market for "agentic commerce," covering personal assistants like Instinct and Town, shopping search tools like Daydream, payment infrastructure startups like Catena Labs and Basis Theory, and marketing tech such as Profound. Major platforms are also moving: OpenAI and Stripe launched the Agentic Commerce Protocol, Google operates the Agent Payments Protocol, and Visa and Mastercard introduced Trusted Agent Protocol and Agent Pay. However, the space faces trust and fraud challenges, illustrated by Phia's cookie-stuffing scandal and an Instinct agent error that cost a user around $300. Investor interest remains strong, with millions raised across the sector, even as enterprise adoption lags due to compliance and security concerns.
- Adobe Analytics reported that 41% of respondents used AI for online shopping in June 2026.
- OpenAI and Stripe launched the Agentic Commerce Protocol (ACP), while Google operates the Agent Payments Protocol.
- Profound raised $96 million in Series C funding led by Lightspeed Venture Partners.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners Creandum and M13 share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks
